These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

785 related items for PubMed ID: 19396600

  • 1. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [Abstract] [Full Text] [Related]

  • 2. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [Abstract] [Full Text] [Related]

  • 3. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
    Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.
    J Med Chem; 2008 Mar 27; 51(6):1976-80. PubMed ID: 18288793
    [Abstract] [Full Text] [Related]

  • 4. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P, Tang Y, Sleczka B, Rodrigues D, Gavai A, Wong T, Christopher L, Zhang H.
    J Pharm Sci; 2010 Aug 27; 99(8):3579-93. PubMed ID: 20166197
    [Abstract] [Full Text] [Related]

  • 5. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
    Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D'Arienzo C, Derbin G, Fargnoli J.
    J Med Chem; 2006 Apr 06; 49(7):2143-6. PubMed ID: 16570908
    [Abstract] [Full Text] [Related]

  • 6. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
    Syed S, Clemens PL, Lathers D, Kollia G, Dhar A, Walters I, Masson E.
    J Clin Pharmacol; 2012 Jun 06; 52(6):914-21. PubMed ID: 21659627
    [Abstract] [Full Text] [Related]

  • 7. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
    Gong J, Gan J, Masson E, Syed S, Xia YQ, Williams D, Pursley J, Jemal M, Humphreys WG, Iyer RA.
    Drug Metab Dispos; 2012 Dec 06; 40(12):2374-80. PubMed ID: 22983304
    [Abstract] [Full Text] [Related]

  • 8. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
    Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS.
    Cancer Res; 2007 Jul 15; 67(14):6899-906. PubMed ID: 17638901
    [Abstract] [Full Text] [Related]

  • 9. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.
    Clin Cancer Res; 2008 Oct 01; 14(19):6146-53. PubMed ID: 18829493
    [Abstract] [Full Text] [Related]

  • 10. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
    El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E.
    Cancer Chemother Pharmacol; 2013 Jul 01; 72(1):53-64. PubMed ID: 23719718
    [Abstract] [Full Text] [Related]

  • 11. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z, Zadjura L, D'Arienzo C, Marino A, Santone K, Klunk L, Greene D, Lin PF, Colonno R, Wang T, Meanwell N, Hansel S.
    Biopharm Drug Dispos; 2005 Dec 01; 26(9):387-402. PubMed ID: 16142720
    [Abstract] [Full Text] [Related]

  • 12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV, Wang J, Lee FY, Marathe PH.
    Cancer Chemother Pharmacol; 2008 Mar 01; 61(3):365-76. PubMed ID: 17429625
    [Abstract] [Full Text] [Related]

  • 13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS, Hatch HL, Kosea F, Nguyen HT, Choo EF, McClure KF, Taylor TJ, Henne KR, Kuperman AV, Dombroski MA, Letavic MA.
    Biopharm Drug Dispos; 2006 Nov 01; 27(8):371-86. PubMed ID: 16944451
    [Abstract] [Full Text] [Related]

  • 14. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
    Prueksaritanont T, Gorham LM, Ellis JD, Fernandez-Metzler C, Deluna P, Gehret JR, Strong KL, Hochman JH, Askew BC, Duggan ME, Gilbert JD, Lin JH, Vyas KP.
    Drug Metab Dispos; 1996 Nov 01; 24(11):1263-71. PubMed ID: 8937862
    [Abstract] [Full Text] [Related]

  • 15. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
    Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R, Mortillo S, Wautlet BS, Krishnan B, Kukral D, Malone H, Lewin AC, Henley BJ, Fargnoli J.
    Mol Cancer Ther; 2010 Feb 01; 9(2):369-78. PubMed ID: 20103604
    [Abstract] [Full Text] [Related]

  • 16. Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
    LoRusso P, Shapiro GI, Hurwitz H, Pilat MJ, Chemidlin J, Kollia G, Syed S, Fischer B, Masson E.
    Cancer Chemother Pharmacol; 2011 Dec 01; 68(6):1377-85. PubMed ID: 21461891
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS, Maurer TS, Kalgutkar AS, Royer LJ, Francone OL, Winter SM, Terra SG, Chen D, Gao X.
    Xenobiotica; 2009 Oct 01; 39(10):766-81. PubMed ID: 19622022
    [Abstract] [Full Text] [Related]

  • 18. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
    Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC.
    Eur J Cancer; 2010 Jun 01; 46(9):1537-53. PubMed ID: 20303261
    [Abstract] [Full Text] [Related]

  • 19. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
    Mekhail T, Masson E, Fischer BS, Gong J, Iyer R, Gan J, Pursley J, Patricia D, Williams D, Ganapathi R.
    Drug Metab Dispos; 2010 Nov 01; 38(11):1962-6. PubMed ID: 20671097
    [Abstract] [Full Text] [Related]

  • 20. Brivanib alaninate for cancer.
    Diaz-Padilla I, Siu LL.
    Expert Opin Investig Drugs; 2011 Apr 01; 20(4):577-86. PubMed ID: 21391890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.